Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide cardiovascular outcomes trial in adults with overweight or obesity and established cardiovascular disease
NL-OMON55704Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight, cardiac morbidity and 3 more comparing Semaglutide plus standard of care with Placebo plus standard of care (2 arms). Started Feb 2019; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweightcardiac morbidityatherosclerotic diseasearteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON55704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55704.